Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
BIOCON | FRESENIUS KABI ONCO. | BIOCON / FRESENIUS KABI ONCO. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.4 | 22.1 | 141.8% | View Chart |
P/BV | x | 3.7 | 3.1 | 120.1% | View Chart |
Dividend Yield | % | 0.3 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
FRESENIUS KABI ONCO. Mar-13 |
BIOCON / FRESENIUS KABI ONCO. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 176 | 401.9% | |
Low | Rs | 554 | 79 | 705.5% | |
Sales per share (Unadj.) | Rs | 91.9 | 37.7 | 243.9% | |
Earnings per share (Unadj.) | Rs | 16.7 | 5.1 | 328.1% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 6.7 | 359.6% | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
Dividend yield (eoy) | % | 0.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.6 | 42.5 | 238.9% | |
Shares outstanding (eoy) | m | 600.00 | 158.23 | 379.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 3.4 | 203.2% | |
Avg P/E ratio | x | 37.7 | 25.0 | 151.0% | |
P/CF ratio (eoy) | x | 26.1 | 18.9 | 137.8% | |
Price / Book Value ratio | x | 6.2 | 3.0 | 207.4% | |
Dividend payout | % | 6.0 | 0 | - | |
Avg Mkt Cap | Rs m | 378,330 | 20,135 | 1,879.0% | |
No. of employees | `000 | 6.1 | 1.2 | 532.2% | |
Total wages/salary | Rs m | 11,653 | 703 | 1,657.1% | |
Avg. sales/employee | Rs Th | 8,994.3 | 5,176.2 | 173.8% | |
Avg. wages/employee | Rs Th | 1,900.7 | 610.4 | 311.4% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 699.6 | 233.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 5,963 | 924.8% | |
Other income | Rs m | 1,444 | 18 | 8,022.2% | |
Total revenues | Rs m | 56,588 | 5,981 | 946.1% | |
Gross profit | Rs m | 15,883 | 1,430 | 1,110.6% | |
Depreciation | Rs m | 4,478 | 258 | 1,736.3% | |
Interest | Rs m | 709 | -26 | -2,726.9% | |
Profit before tax | Rs m | 12,140 | 1,216 | 998.2% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -68 | 0.0% | |
Tax | Rs m | 2,123 | 342 | 620.4% | |
Profit after tax | Rs m | 10,026 | 806 | 1,244.1% | |
Gross profit margin | % | 28.8 | 24.0 | 120.1% | |
Effective tax rate | % | 17.5 | 28.1 | 62.2% | |
Net profit margin | % | 18.2 | 13.5 | 134.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 5,102 | 945.4% | |
Current liabilities | Rs m | 30,376 | 2,385 | 1,273.4% | |
Net working cap to sales | % | 32.4 | 45.6 | 71.1% | |
Current ratio | x | 1.6 | 2.1 | 74.2% | |
Inventory Days | Days | 68 | 150 | 45.5% | |
Debtors Days | Days | 86 | 113 | 75.5% | |
Net fixed assets | Rs m | 64,130 | 5,148 | 1,245.7% | |
Share capital | Rs m | 3,000 | 158 | 1,896.3% | |
"Free" reserves | Rs m | 57,980 | 6,556 | 884.4% | |
Net worth | Rs m | 60,980 | 6,732 | 905.8% | |
Long term debt | Rs m | 15,766 | 952 | 1,655.7% | |
Total assets | Rs m | 121,924 | 10,388 | 1,173.7% | |
Interest coverage | x | 18.1 | -45.8 | -39.6% | |
Debt to equity ratio | x | 0.3 | 0.1 | 182.8% | |
Sales to assets ratio | x | 0.5 | 0.6 | 78.8% | |
Return on assets | % | 8.8 | 7.5 | 117.3% | |
Return on equity | % | 16.4 | 12.0 | 137.3% | |
Return on capital | % | 16.8 | 14.6 | 114.7% | |
Exports to sales | % | 28.1 | 74.5 | 37.8% | |
Imports to sales | % | 18.9 | 24.8 | 76.1% | |
Exports (fob) | Rs m | 15,506 | 4,441 | 349.2% | |
Imports (cif) | Rs m | 10,399 | 1,477 | 703.9% | |
Fx inflow | Rs m | 15,506 | 5,298 | 292.7% | |
Fx outflow | Rs m | 10,399 | 1,772 | 586.8% | |
Net fx | Rs m | 5,107 | 3,525 | 144.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 1,274 | 906.2% | |
From Investments | Rs m | -7,138 | -1,204 | 592.8% | |
From Financial Activity | Rs m | -2,417 | -196 | 1,232.5% | |
Net Cashflow | Rs m | 2,103 | -126 | -1,665.1% |
Indian Promoters | % | 40.4 | 0.0 | - | |
Foreign collaborators | % | 20.6 | 81.0 | 25.4% | |
Indian inst/Mut Fund | % | 8.4 | 0.3 | 2,800.0% | |
FIIs | % | 10.7 | 9.6 | 111.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 9.1 | 218.7% | |
Shareholders | 109,995 | 42,599 | 258.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: NOVARTIS TORRENT PHARMA DISHMAN PHARMA CIPLA ABBOTT INDIA
Compare BIOCON With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More